UroGen Pharma
URGN
101 hedge funds and large institutions have $248M invested in UroGen Pharma in 2023 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 8 closing their positions.
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
105% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $509K
82% more capital invested
Capital invested by funds: $137M → $248M (+$112M)
59% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 22
19% more funds holding
Funds holding: 85 → 101 (+16)
2.2% more ownership
Funds ownership: 56.33% → 58.53% (+2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$42.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$23.8M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$8.17M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.97M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$4.93M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.64M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.01M |
| 4 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$3.64M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$3.39M |
URGN Hedge Fund Activity: Q3 2023 in Review
101 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q3 2023, worth a combined $248M — up 82% from $137M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new URGN positions and 8 closed out — a net gain of 16 holders — while 35 added to existing stakes and 22 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $42.1M. The largest seller was Clal Insurance, cutting an estimated $4.93M.
- 101 institutional investors held UroGen Pharma (URGN) as of Q3 2023, up from 85 in Q2 2023.
- Funds reported $248M of UroGen Pharma stock for Q3 2023, up 82% quarter-over-quarter.
- 24 funds opened new UroGen Pharma positions in Q3 2023 and 8 closed out, a net change of +16 holders.
- The largest UroGen Pharma buyer in Q3 2023 was Great Point Partners, an estimated $42.1M added.
- The largest UroGen Pharma seller in Q3 2023 was Clal Insurance, an estimated $4.93M sold.
Based on aggregated 13F filings for Q3 2023.